Home / Learn / Oncology Pharmacy / Advisory Committee

Advisory Committee

Olalekan Ajayi, PharmD, MBA
Director of Practice Transformation
Sheridan Memorial Hospital
Sheridan, WY

Olalekan “Lekan” Ajayi, PharmD, MBA, is oncology service line manager at Sheridan Memorial Hospital in Sheridan, Wyoming. In this role, Dr. Ajayi oversees both strategic and operational initiatives of the oncology and internal medicine programs. He has also worked extensively as a clinical pharmacist and an oncology pharmacy manager for eight years.

Dr. Ajayi currently serves on the ACCC Board of Trustees and has worked on a number of ACCC initiatives.

He is passionate about patient access to quality cancer care in rural communities. Specifically, Dr. Ajayi is interested in expanding patient access to oncology clinical trials and is working with ACCC on ways to overcome the challenges of patient accruals for clinical trials in rural cancer programs.

He holds a Doctor of Pharmacy degree from the University of Wyoming, and a Master’s in Business Administration from the University of Colorado, Denver.

Melody Chang
Melody Chang, RPh, MBA, BCOP
Director of Pharmacy Operations
Florida Cancer Specialists & Research Institute
Fort Myers, Florida
Melody Chang, RPh, MBA, BCOP, is the director of pharmacy operations for the Florida Cancer Specialists and for the American Oncology Network. She provides strategic leadership and direction to over 100 clinics with clinical and business perspectives. In her role, she assists on drug procurement, develops drug utilization and formulary initiatives that ensure cost-effectiveness and optimized therapeutic outcomes.

In addition, Melody provides guidance on pharmacy clean-room design, ensuring that the pharmacy is in compliance with regulatory requirements. 

Melody currently serves as pharmacist liaison to the Florida Society of Clinical Oncology (FLASCO) Board of Directors.

Jorge Garcia
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Assistant Vice President - System Oncology Pharmacy Services, Non-Oncology Infusion Center Pharmacy Services
Miami Cancer Institute, Baptist Health South Florida
Miami, Florida

Jorge J. García, PharmD, MS, MHA, MBA, FACHE, serves as an assistant vice president at Baptist Health South Florida with responsibility for system-wide oncology pharmacy services primarily at the Miami Cancer Institute, the Lynn Cancer Institute, and inpatient oncology pharmacy services at several acute hospitals. Dr. García has pioneered pharmacy charge integrity and revenue management in the health-system setting and is a thought leader and national speaker in this area, as well as in the areas of alternative payment models, biosimilars, and value-based oncology care. Dr. García leads advocacy efforts at the national level to promote evaluation of safe and effective use of biosimilars, along with stakeholder engagement to support a more just and sustainable biosimilar pharmacoeconomics model.   

Dr. García obtained his Doctor of Pharmacy and MBA from Nova Southeastern University in 2010. He then transitioned to the University of Pittsburgh Medical Center to pursue an ASHP-accredited PGY-1 & PGY-2 Health-System Pharmacy Administration Residency and a Master of Science in Pharmacy Administration. He also completed an MHA from Florida Atlantic University. Dr. García is a board member at the Florida Society of Clinical Oncology (FLASCO), a recipient of the FLASCO 2018 Above and Beyond Award, and a fellow of the American College of Healthcare Executives. 

Sandeep Parsad
Sandeep Parsad, PharmD, MBA, BCOP
Assistant Pharmacy Director, Cancer & Investigational Drug Services;
Director, PGY2 Oncology Pharmacy Residency Program
University of Chicago Medicine
Chicago, Illinois

Sandeep Parsad, PharmD, MBA, BCOP, is the assistant director of pharmacy at the University of Chicago Medicine. She is the director of the PGY2 oncology pharmacy residency program, co-chair of the Oncology Drug Safety Committee, and oversees hematology/oncology and investigational drug services. 

Dr. Parsad has a strong interest in stem cell transplantation, hematologic malignancies, value-based payment models, and oncology quality initiatives.